Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.08.1596 on November 20 2006

Journal of Clinical Oncology, Vol 24, No 36 (December 20), 2006: pp. 5703-5710
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adès, L.
Right arrow Articles by Fenaux, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adès, L.
Right arrow Articles by Fenaux, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

Lionel Adès, Sylvie Chevret, Emmanuel Raffoux, Stephane de Botton, Agnes Guerci, Arnaud Pigneux, Anne Marie Stoppa, Thierry Lamy, Francoise Rigal-Huguet, Anne Vekhoff, Sandrine Meyer-Monard, Frederic Maloisel, Eric Deconinck, Augustin Ferrant, Xavier Thomas, Nathalie Fegueux, Christine Chomienne, Herve Dombret, Laurent Degos, Pierre Fenaux

From the Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service d'Hématologie Clinique, Paris 13 University, Bobigny; Hospital Saint Louis; Hotel Dieu, Paris; Centre Hospitalier Universitaire (CHU), Lille; CHU Nancy; CHU Bordeaux; Institut Paoli-Calmettes, Marseille; CHU Rennes; CHU Toulouse; CHU Strasbourg; CHU Besancon; CHU Lyon; CHU Montpellier, France; Universitatsspital Basel, Basel, Switzerland; and the Université Catholique de Louvain, Brussels, Belgium

Address reprint requests to Pierre Fenaux, MD, PhD, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service d'Hématologie Clinique, Paris 13 University, 125 rue de Stalingrad, 93009 Bobigny, France; e-mail: pierre.fenaux{at}avc.aphp.fr

PURPOSE: Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therapy, and we aimed at confirming this finding in a randomized trial.

PATIENTS AND METHODS: Newly diagnosed APL patients younger than age 60 years with a WBC count of less than 10,000/µL were randomly assigned to receive either ATRA combined with and followed by three daunorubicin (DNR) plus AraC courses and a 2-year maintenance regimen (AraC group) or the same treatment but without AraC (no AraC group). Patients older than age 60 years and patients with initial WBC count of more than 10,000/µL were not randomly assigned but received risk-adapted treatment, with higher dose of AraC and CNS prophylaxis in patients with WBC counts more than 10,000/µL.

RESULTS: Overall, 328 (96.5%) of 340 patients achieved complete remission (CR). In the AraC and the no AraC groups, the CR rates were 99% and 94% (P = .12), the 2-year cumulative incidence of relapse (CIR) rates were 4.7% and 15.9% (P = .011), the event-free survival (EFS) rates were 93.3% and 77.2% (P = .0021), and survival rates were 97.9% and 89.6% (P = .0066), respectively. In patients younger than age 60 years with WBC counts more than 10,000/µL, the CR, 2-year CIR, EFS, and survival rates were 97.3%, 2.9%, 89%, and 91.9%, respectively.

CONCLUSION: These results support a role for AraC in addition to ATRA and anthracyclines in the treatment of newly diagnosed APL, at least using DNR at the cumulative dose we used and with the consolidation and maintenance regimens we used.

published online ahead of print at www.jco.org on November 20, 2006.

Supported by the Programme Hospitalier de Recherche Clinique and the Centre Hospitalier Universitaire of Lille-France, the Association pour la Recherche sur le Cancer, and the Ligue Contre le Cancer (Comité du Nord).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
haematolHome page
P. Montesinos, J. Diaz-Mediavilla, G. Deben, V. Prates, M. Tormo, V. Rubio, I. Perez, I. Fernandez, M. Viguria, C. Rayon, et al.
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, September 1, 2009; 94(9): 1242 - 1249.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al.
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood, February 26, 2009; 113(9): 1875 - 1891.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, et al.
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
J. Clin. Oncol., February 1, 2009; 27(4): 504 - 510.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Montesinos, J. M. Bergua, E. Vellenga, C. Rayon, R. Parody, J. de la Serna, A. Leon, J. Esteve, G. Milone, G. Deben, et al.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
Blood, January 22, 2009; 113(4): 775 - 783.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Z.-Y. Wang and Z. Chen
Acute promyelocytic leukemia: from highly fatal to highly curable
Blood, March 1, 2008; 111(5): 2505 - 2515.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Ades, M. A. Sanz, S. Chevret, P. Montesinos, P. Chevallier, E. Raffoux, E. Vellenga, A. Guerci, A. Pigneux, F. Huguet, et al.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
Blood, February 1, 2008; 111(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. S. Tallman and J. K. Altman
Curative Strategies in Acute Promyelocytic Leukemia
Hematology, January 1, 2008; 2008(1): 391 - 399.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Asou, Y. Kishimoto, H. Kiyoi, M. Okada, Y. Kawai, M. Tsuzuki, K. Horikawa, M. Matsuda, K. Shinagawa, T. Kobayashi, et al.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
Blood, July 1, 2007; 110(1): 59 - 66.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Lo-Coco, E. Ammatuna, and M. A. Sanz
Current treatment of acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 289 - 291.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online